anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Menorrhagia is a common clinical problem. Morbid events include dysmenorrhea, hospitalizations, red blood cell transfusions, and quality of life impairment in terms of daily activities, chronic pain, and time lost from work and or school. Up to 60% of women with uncontrolled menorrhagia undergo hysterectomy. Up to 20% of women with menorrhagia may have undiagnosed von Willebrand disease (vWd), or other bleeding disorders. Prevalence of vWd in the general population is estimated at just over 1%. Intuitively, the prevalence of vWd in women with menorrhagia is probably higher since platelet plug formation is necessary for menstrual hemostasis. Current management of menorrhagia in patients in the United States often begins with hormonal therapy. Estrogen and estrogen derivatives in oral contraceptives have been shown to increase von Willebrand factor (vWf) levels. Women with menorrhagia who have vWd or who are hemophilia A carriers have also been successfully treated with desmopressin acetate (DDAVP, Stimate® Nasal Spray). Tranexamic acid (Cyklokapron) is utilized extensively for menorrhagia in Australia and the United Kingdom. Standard hormonal therapy has not been compared with desmopressin or antifibrinolytics for menorrhagia. This study will compare treatment options for women with menorrhagia who have a detectable bleeding disorder. Investigators will document the effect on quality of life, menstrual flow, and coagulation parameters of treatment with oral contraceptive pills, desmopressin, or tranexamic acid.
This is a double-blind clinical trial. All subjects will be sent an instructional video and be given written instructions which will educate them on how to use the drug or placebo nasal spray. Patients will follow the dosing instructions for Astepro® 0.15% nasal spray.
The invention discloses traditional Chinese medicine gargle for treating gingivitis. Gingivitis is one of the most common oral diseases, the effectiveness of traditional treatment has been widely confirmed, but adverse reactions are numerous, the taste is poor and the effect is not ideal. The traditional Chinese medicine gargle disclosed by the invention is prepared from the following traditional Chinese medicine: polygonum runcinatum, sedum verticallatum, stylophorum lasiocarpum (Oliv.) Fedde, Heteropanax fragrans(Roxb.)Seem, fuzhou diospyros root, ophioglossum vulgatum, maidenhair spleenwort, straightstalk alpine meadowrue root, woody-rhizomed fimbristylis herb, polytrchum commune, Alectoria asiatica du rietz, king pedicularis root and rust-brown crotalaria. Clinical trials prove that the total efficiency reaches 97.50%, and the curative effect is remarkable.
In standard preclinical in vivo lifetime carcinogenicity studies, an unexpectedly high incidence of pancreatic acinar adenocarcinomas was identified in male, but not female, rats. (See PRECAUTIONS, Carcinogenesis, Mutagenesis, Impairment of Fertility.) The clinical significance of this finding is unknown. Clinical experience during gabapentin’s premarketing development provides no direct means to assess its potential for inducing tumors in humans.

In clinical studies in adjunctive therapy in epilepsy comprising 2085 patient-years of exposure in patients > 12 years of age, new tumors were reported in 10 patients (2 breast, 3 brain, 2 lung, 1 adrenal, 1 non-Hodgkin’s lymphoma, 1 endometrial carcinoma in situ), and preexisting tumors worsened in 11 patients (9 brain, 1 breast, 1 prostate) during or up to 2 years following discontinuation of gabapentin. Without knowledge of the background incidence and recurrence in a similar population not treated with gabapentin, it is impossible to know whether the incidence seen in this cohort is or is not affected by treatment.
Novelty: a method for the preparation of natural olive oil-soap is disclosed. Composition: 41 % virgin olive oil which is rich in A, E, K vitamin content, trace elements (Ca,Fe,K, Na,Zn,Cu,Mn,Se), aminoacids, high-concentration squalene content, flavones, copper, Ferrum, Magnesium and vitamin C; grape seed oil rich in vitamins A, B2,B2,B6 and E and very rich in linoleic oil; castor oil rich in Ω-9, vitamin E and ricinoleic acid as main component; Agiorgitiko red wine rich in polyphenols, resveratrol, flavonoids, potassium, and glycerol. Preparation mode: use of natural components and absolute natural methods. The soft treatment of the raw materials implies the conservation of the natural properties of the components in the final product. The concentration of the aqueous NAOH solutionis analogously reduced so that full saponification is prevented and the existence of free oils in the final product preserved for boosting the hydrating character of the final product (overfatting of 10%). The afresh addition of a mixture of oils at the final saponification stage enhances the oil content of the soap preparation. Maturation and drying is realized by the passage of time without anyother intervention.
PURPOSE:To provide a new-type analgesic containing an analgesic and an antibody against an endogenous algesic substance and a pain information transmission substance, having excellent analgesic effect and low toxicity and free from side effect. CONSTITUTION:An antibody is produced e.g. by administering proper amounts of an endogenous algesic substance (e.g. bradykinin), a pain-promoting substance (e.g. prostaglandin) and a pain information transmission substance (e.g. substance P) to a proper animal and collecting the antibody after a prescribed period. The antibody is used in combination with a physically and chemically treated fragment and a conventional anti-inflammatory analgesic antipyretic agent (e.g. aspirin) or in the form of a composite material containing the antibody chemically bonded with the known analgesic. The antibody treatment is carried out e.g. by an organic solvent treatment with alcohol, enzymatic treatment with pepsin, etc., acid treatment at pH 4, chemical treatment by sulfonation reaction, etc.
CAY-1 is a fungicidal saponin from the cayenne pepper ( Capsicum frutescens ) fruit. The saponins 1081 and 919, closely elute with, and are close structural relatives of, CAY-1. Saponin 1081 is poorly antifungal while 919 has no antifungal properties. Nongerminated and germinating conidia of  Aspergilus flavus, A. fumigatus, A. niger, Fusarium oxysporum, F. solani , and  F. verticilioides  were tested against pure CAY-1 and CAY-1:1081:919 at ratios of 8:1:1, 6:2:2 and 4:3:3 and efficacy was determined after various incubation times. Pure CAY-1 and all saponin mixtures were significantly (p<0.001) lethal to the germinating conidia of  A. flavus, A. niger , and  F. solani . All saponin mixtures were equal or superior to pure CAY-1 in antifungal properties. Mixtures of the naturally occurring inactive or poorly fungicidal saponins with reduced levels of CAY-1 display superior fungicidal properties when compared to pure CAY-1 at the same dose levels.
Visit 1: Participants' cognition is measured using digital tests. Visit 2: Participants' cognition is measured using paper-pencil tests.
The present invention generally relates to systems and methods for monitoring and/or providing feedback for drugs or other pharmaceuticals taken by a subject. In one aspect, the present invention is directed to devices and methods for determining a species within the skin of a subject; and producing feedback to a subject based on the determination of the species. The feedback may be, for example, visual, audible, tactile, a change in temperature, etc. In some cases, information regarding the determination of the species may be transmitted to another entity, e.g., a health care provider, a computer, a relative, etc., which may then provide feedback to the subject in some fashion. In some cases, the feedback may be directly indicative of the species, e.g., whether the species is present, the concentration of the species, whether a by-product of a reaction involving the species is present, whether a compound affected by the species is present, etc. However, the feedback may also be indirect in some embodiments. For example, the subject may be presented with an external reward, e.g., based on the determination of the species within the skin. For instance, a reward such as cash, coupons, songs, discounts, personal items, etc., may be offered based on the level of compliance of the subject. Still other aspects of the invention are generally directed to kits involving such devices (with or without the drug to be monitored), methods of promoting such systems, or the like.
In all study rooms, a biocentric lighting environment will be able to be created by activating a special lighting system. In these rooms, light will change dynamically both in spectral distribution and intensity during the day. During the day, color temperature and intensity are high (1000 lux and up to 6500 K) to decrease both intensity and color temperature during the evening.
The systems and methods, in one embodiment, include a convolutional neural network (CNN) model trained by a modified version of the CycleGAN process. The CNN filters ultrasound images generated by a handheld ultrasound device to generate images that are perceptually similar to images generated by a cart-based ultrasound device in terms of quality. The resulting images look sharper and less noisy compared to the original inputs. The invention is a tool within the actions menu of a mobile app. When the tool is open, users can turn filtering on and off. The users will turn filtering on to reduce noise so they can reach the right scanning spot faster. After which because of body habitus, still there might be some noise that this tool can clean up. The user can then decide to have the filtering on or off during the diagnostic process.
Prior to applying Virasal, soak wart in warm water for five minutes. Remove any loosened tissue by gently rubbing with a brush, wash cloth, or emery board. Dry wart site thoroughly. Using the brush applicator supplied, apply Virasal twice to entire wart surface, allowing the first application to dry before applying the second. Continue treatment once or twice a day as directed by physician. Be careful not to apply to surrounding skin. 

Clinically visible improvement will normally occur during the first or second week of therapy. Maximum resolution may be expected after four to six weeks of Virasal use.
<P>PROBLEM TO BE SOLVED: To provide a soft capsule preparation stable over a long period while holding excellent characteristics essential to gelatin.  <P>SOLUTION: This soft capsule preparation is obtained by filling a capsule substrate consisting essentially of the gelatin with required contents. The gelatin is prepared by dissolving thereof in electrolytic reduction water. Furthermore, the electrolytic reduction water has pH8-10 thereof and 0 to -350 mV oxidation reduction potential. An antioxidant, a turmeric-containing substance or a squalene-containing substance is used as the contents for filling.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Proposed is a three-arm randomized controlled trial of 6-months of weight loss counseling (i.e., dietary-induced caloric restriction and physical activity) on clinically meaningful endpoints in 100 breast cancer survivors . The three arms will be: 1. In-person counseling, 2. Telephone-based counseling, 3. Usual care. Women will be randomized into one of 3 study arms using a random permuted block design. Research staff collecting body composition data, as well as reviewing forms and entering data, will be blinded to the participant's study group.
FIELD: pharmacy. SUBSTANCE: invention relates to composition for controlled-release of stimulating agent - xanthine or its derivative, for example, caffeine and method of its preparing. Composition is used for courage and/or somnolence increase. Composition has microparticles of stimulating agent and biodegradable matrix from which the stimulating agent is released for the long time. Composition is used by orally route. For 2 h after the preparation ingestion 20-50 wt.-% of stimulating agent is released and remained part - for 8-10 h after intake. Binding agent is water-soluble material which is bound to the stimulating agent and distributed in its uniformly as solid particles. Agent that retards the release of the stimulating agent from composition is water-insoluble material. Composition consists of microparticles containing spherical core made of pharmaceutically acceptable organic material. Core is covered by the first and the second matrix layers. The first matrix layer has 55-95% of stimulating agent and the second one - 5-45% of its total amount. For additional inhibition of stimulating agent release from matrix an intermediate cover can be between matrix layers. In part, the core can include polysaccharide, sugar and sugar derivative. Synthetic polymer can be used as water-soluble material and shellac - as water-insoluble material. Caffeine can be used as the stimulating agent. Amount of stimulating agent in the first layer is 80-90% and in the second layer - 10-20 preferably. Invention claims the composition described above that is composed of many microparticles closed into capsule and the method of preparing compositions involving preparing solid spherical cores and applying two layers of envelopes on their surface. Compositions of layers are given above. Application of envelope layers is carried out by spraying the stimulating agent mixture, binding agent from water-soluble material and agent inhibiting release of the stimulating agent. Core have preferable initial diameter 350-1000 mcm and stimulating agent exists as powder (particles size is less 100 mcm). In the process of the composition preparing humidity value should be regulated at the level below 5%. Invention provides effect for some hours without increase of the stimulating agent level that can show undesirable effects. EFFECT: enhanced effectiveness of composition, improved method of preparing. 15 cl, 5 dwg, 10 ex
The present invention relates to the treatment of cancer. NUPR1 is a nuclear intrinsically disordered protein (IDP) of 82 amino acids long that play an important role in pancreatic ductal adenocarcinoma (PDAC) as well as other cancers since its genetic inactivation by genetic or pharmacological approaches induces tumors growth arrest and/or regression. The inventors recently developed an efficient multidisciplinary strategy by combining biophysical, biochemical, bioinformatic and biological approaches for a molecular screening to select potential drug candidates against NUPR1. A family of TFP-derived compounds was produced and the most active one, named ZZW-115, showed more than 10 times efficient antitumor activity on a large panel of primary PDAC-derived cells and several non-pancreatic cancer cells. More, they showed that treatment with ZZW-115 sensitizes cancer cells to genotoxic-induced DNA damage. Thus, the present invention relates to a combination of an inhibitor of NUPR1 and a genotoxic treatment for use in the treatment of a cancer in a subject in need thereof. Particularly, the invention is defined by its claims.
Untreated pain will also cause long term impact on newborns,Some scientists in foreign countries have done some research on rats, they found that if rats were exposed to pain for a long time, its nociception neural circuit's development will be harmed, and the pain threshold will be lowered. For newborns, untreated pain will cause hypalgesia when they are in puberty and hyperalgesia after adulthood. The experience of pain in infancy also affects the babies' later life after they grow up, it may cause emotional problems, minimal brain dysfunction, social intercourse defect and so on. So it is very important to find out useful interventions to decrease pain in newborns, considering the long term impact and side effect of medicine, it is seldom to use medical interventions to decrease pain. Non-pharmacological interventions become quite important. In foreign countries, there have been kinds of useful non-pharmacological interventions such as kangaroo care, breast-feeding, sucrose and non-nutritive sucking. While in China, there are massage, positioning, sucrose, music and kangaroo care that proved to be effective to decrease pain in newborns. The investigators find few reports about breastfeeding or non-nutritive sucking's effect of decreasing pain in term newborns. For breast-feeding, it includes the nursing mother who has consoling impact, hugging, attention transferring, taste, the breast milk contains tryptophane, which is the precursor of N-acetyl-5-O-T that can raise up the density of β-endorphin, β-endorphin has analgesic effect. For non-nutritive sucking, it also contains attention transferring. It is said that non-nutritive sucking can raise up the pain threshold through stimulating the oral tactile recipient, or promote the releasing of 5-HT that modulates pain. Non-nutritive sucking can also lower the sensitivity of peripheral nerves.
This protocol utilizes a cross-sectional study design. Over a 5-year period, the investigators will enroll patients who have clinical and lab features characteristic of a PID disorder or PCD, but do not have a confirmed genetic diagnosis. Innovative, standardized methods (SOPs) will be utilized, including ciliary ultrastructural analyses by transmission electron microscopy (TEM), as pertinent. Measures of nasal nitric oxide (nNO) will be performed in all subjects to allow comparisons of nNO values in PID vs. PCD. Patients with high likelihood of a PID disorder or a high likelihood of PCD will initially undergo research genetic testing on a commercial approved panel for PID disorders or a panel of at least 37 PCD genes. All subjects who do not have a genetic diagnosis from the test panels will undergo whole exome sequencing (WES) to search for novel genetic etiologies for PID or PCD.
In this group , injection of GnRH agonist (Superfact) at a subcutaneous daily dose of 0.5 mg is started on the day 17-19 of the natural menstrual cycle. Once pituitary desensitization is confirmed, hormonal treatment is commenced with 4mg/day oral Estradiol valerate and after 7 days if endometrial thickness is adequate, Estradiol administration will be continued with the same dose and 100mg Progesterone is administered before embryo transfer, otherwise patients are candidates for higher dosage of Estradiol till favourable endometrial thickness is achieved.
The efficacy and safety of Prolia in the treatment to increase bone mass in men with osteoporosis was demonstrated in a 1-year, randomized, double-blind, placebo-controlled trial. Enrolled men had a baseline BMD T-score between -2.0 and -3.5 at the lumbar spine or femoral neck. Men with a BMD T-score between -1.0 and -3.5 at the lumbar spine or femoral neck were also enrolled if there was a history of prior fragility fracture. Men with other diseases (such as rheumatoid arthritis, osteogenesis imperfecta, and Paget's disease) or on therapies that may affect bone were excluded from this study. The 242 men enrolled in the study ranged in age from 31 to 84 years with a mean age of 65 years. Men were randomized to receive SC injections of either placebo (n = 121) or Prolia 60 mg (n = 121) once every 6 months. All men received at least 1000 mg calcium and at least 800 IU vitamin D supplementation daily.

Effect on Bone Mineral Density (BMD)

The primary efficacy variable was percent change in lumbar spine BMD from baseline to 1-year. Secondary efficacy variables included percent change in total hip, and femoral neck BMD from baseline to 1-year.

Treatment with Prolia significantly increased BMD at 1-year. The treatment differences in BMD at 1-year were 4.8% (+0.9% placebo, +5.7% Prolia; (95% CI: 4.0, 5.6); p < 0.0001) at the lumbar spine, 2.0% (+0.3% placebo, +2.4% Prolia) at the total hip, and 2.2% (0.0% placebo, +2.1% Prolia) at femoral neck. Consistent effects on BMD were observed at the lumbar spine regardless of baseline age, race, BMD, testosterone concentrations, and level of bone turnover.

Bone Histology and Histomorphometry

A total of 29 transiliac crest bone biopsy specimens were obtained from men with osteoporosis at 12 months (17 specimens in Prolia group, 12 specimens in placebo group). Of the biopsies obtained, 29 (100%) were adequate for qualitative histology and, in Prolia patients, 6 (35%) were adequate for full quantitative histomorphometry assessment. Qualitative histology assessments showed normal architecture and quality with no evidence of mineralization defects, woven bone, or marrow fibrosis in patients treated with Prolia. The presence of double tetracycline labeling in a biopsy specimen provides an indication of active bone remodeling, while the absence of tetracycline label suggests suppressed bone formation. In patients treated with Prolia, 6% had no tetracycline label present at the month 12 biopsy, while 100% of placebo-treated patients had double label present. When compared to placebo, treatment with Prolia resulted in markedly reduced bone formation rates. However, the long-term consequences of this degree of suppression of bone remodeling are unknown.
The group receive placebo of MSCs and oral Mycophenolate Mofetil of 2.0g/d. .
PURPOSE:To obtain on excellent thickener suitable for cosmetics and an ink, etc., by cross-linking a carboxyl group of the copolymer of (meth)acrylic acid and an alkaline metal salt of (meth)allyl sulfonic acid with a fatty acid and an aluminum salt thereof followed by converting the sulfonic acid group of the obtd. copolymer to a quaternary ammonium salt thereof. CONSTITUTION:The titled thickener is formed by adding >=6C the fatty acid such as 2-ethyl hexanoic acid to a solution of the copolymer of acrylic acid or methacrylic acid and an alkaline metal salt of allyl or methallylsulfonic acid, and by adding an alkaline salt and an aluminum salt such as aluminum nitrate successively to form an aluminum cross-linked product, and subsequently, by converting the sulfonic acid group of the obtd. cross-linked product to the alkaline metal salt thereof, followed by reacting the obtd. salt with a quaternary ammonium salt such as distearyl dimethyl ammonium chloride and recovering, drying said salt. The obtd. oil type thickener is easy to produce, and is especially, easy to thicken and gelatinize a petroleum hydrocarbon, and said thickener has excellent transparency.
The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg extemporaneously prepared osmotic capsule with target release rate of approximately 6 hours (EP-Osmotic Capsule-Fast) and C) a single dose of 10 mg extemporaneously prepared osmotic capsule with target release rate of approximately 14 hours (EP-Osmotic Capsule-Slow). Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.